France generics association GEMME to hold symposium in support of domestic biosimilar production

6 October 2014
biosimilars_samples_large

The French generics-maker association, GEMME, is to hold the first symposium on the challenges and opportunities associated with biosimilars in France, and is urging the industry to nurture the nascent biosimilars trade domestically.

The complexity and resources needed for the development and production of biosimilars mean that France as a country needs to prioritize favorable conditions for the industry to flourish.

The GEMME symposium will consist of health economists, representatives from industry, research, hospitals and patients, and will encourage those involved to reach a consensus on how to develop these specialities in France.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biosimilars